SOBI Statistics
Total Valuation
Swedish Orphan Biovitrum AB has a market cap or net worth of SEK 109.61 billion. The enterprise value is 125.94 billion.
Market Cap | 109.61B |
Enterprise Value | 125.94B |
Important Dates
The next estimated earnings date is Thursday, October 24, 2024.
Earnings Date | Oct 24, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Swedish Orphan Biovitrum AB has 342.53 million shares outstanding. The number of shares has increased by 11.41% in one year.
Shares Outstanding | 342.53M |
Shares Change (YoY) | +11.41% |
Shares Change (QoQ) | +0.20% |
Owned by Insiders (%) | 0.23% |
Owned by Institutions (%) | 55.77% |
Float | 218.79M |
Valuation Ratios
The trailing PE ratio is 50.98 and the forward PE ratio is 24.66. Swedish Orphan Biovitrum AB's PEG ratio is 0.87.
PE Ratio | 50.98 |
Forward PE | 24.66 |
PS Ratio | 4.56 |
PB Ratio | 3.02 |
P/FCF Ratio | 17.32 |
PEG Ratio | 0.87 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.40, with an EV/FCF ratio of 19.91.
EV / Earnings | 58.71 |
EV / Sales | 5.31 |
EV / EBITDA | 15.40 |
EV / EBIT | 27.22 |
EV / FCF | 19.91 |
Financial Position
The company has a current ratio of 0.73, with a Debt / Equity ratio of 47.03.
Current Ratio | 0.73 |
Quick Ratio | 0.49 |
Debt / Equity | 47.03 |
Debt / EBITDA | 2.09 |
Debt / FCF | 2.70 |
Interest Coverage | 3.15 |
Financial Efficiency
Return on equity (ROE) is 6.63% and return on invested capital (ROIC) is 5.26%.
Return on Equity (ROE) | 6.63% |
Return on Assets (ROA) | 3.88% |
Return on Capital (ROIC) | 5.26% |
Revenue Per Employee | 13.38M |
Profits Per Employee | 1.21M |
Employee Count | 1,772 |
Asset Turnover | 0.32 |
Inventory Turnover | 1.36 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +54.85% in the last 52 weeks. The beta is 0.23, so Swedish Orphan Biovitrum AB's price volatility has been lower than the market average.
Beta (5Y) | 0.23 |
52-Week Price Change | +54.85% |
50-Day Moving Average | 287.01 |
200-Day Moving Average | 273.00 |
Relative Strength Index (RSI) | 67.23 |
Average Volume (20 Days) | 402,035 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Swedish Orphan Biovitrum AB had revenue of SEK 23.71 billion and earned 2.15 billion in profits. Earnings per share was 6.28.
Revenue | 23.71B |
Gross Profit | 18.42B |
Operating Income | 4.63B |
Pretax Income | 2.61B |
Net Income | 2.15B |
EBITDA | 8.03B |
EBIT | 4.63B |
Earnings Per Share (EPS) | 6.28 |
Balance Sheet
The company has 779.00 million in cash and 17.10 billion in debt, giving a net cash position of -16.32 billion or -47.64 per share.
Cash & Cash Equivalents | 779.00M |
Total Debt | 17.10B |
Net Cash | -16.32B |
Net Cash Per Share | -47.64 |
Equity (Book Value) | 36.35B |
Book Value Per Share | 106.08 |
Working Capital | -4.35B |
Cash Flow
In the last 12 months, operating cash flow was 6.72 billion and capital expenditures -389.00 million, giving a free cash flow of 6.33 billion.
Operating Cash Flow | 6.72B |
Capital Expenditures | -389.00M |
Free Cash Flow | 6.33B |
FCF Per Share | 18.47 |
Margins
Gross margin is 77.69%, with operating and profit margins of 19.51% and 9.05%.
Gross Margin | 77.69% |
Operating Margin | 19.51% |
Pretax Margin | 11.02% |
Profit Margin | 9.05% |
EBITDA Margin | 33.88% |
EBIT Margin | 19.51% |
FCF Margin | 26.68% |
Dividends & Yields
Swedish Orphan Biovitrum AB does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -11.41% |
Shareholder Yield | -11.41% |
Earnings Yield | 1.96% |
FCF Yield | 5.77% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |